Precision BioSciences(DTIL)
DURHAM, NC
Biotechnology1 H-1B visas (FY2023)Focus: Genome-editing enzymes, CAR-T
Precision BioSciences is a life sciences company focused on Genome-editing enzymes, CAR-T.
Cell Therapy
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (7)
3 discontinued products not shown
AMMONIA N 13
ammonia n-13
Post-LOE
INTRAVENOUS · INJECTABLE
Radiopharmaceutical Activity
2015
30
DOXYCYCLINE HYCLATE
doxycycline hyclate
Post-LOE
INJECTION · INJECTABLE
Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile, and excreted in the urine and feces at high concentrations and in a biologically active form. Doxycycline is virtually completely absorbed after oral administration. Following a 200 mg dose, normal adult volunteers averaged peak serum levels of 2.6 mcg/mL of doxycycline at 2 hours, decreasing to 1.45 mcg/mL at 24 hours. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min.). This percentage excretion may fall as low as 1-5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min.). Studies have shown no significant difference in serum half-life of doxycycline (range 18-22 hours) in individuals with normal and severely impaired renal function. Hemodialysis does not alter serum half-life. Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues. Population pharmacokinetic analysis of sparse concentration-time data of doxycycline following standard of care intravenous and oral dosing in 44 pediatric patients (2-18 years of age) showed that allometrically -scaled clearance (CL) of doxycycline in pediatric patients ≥2 to ≤8 years of age (median [range] 3.58 [2.27-10.82] L/h/70 kg, N =11) did not differ significantly from pediatric patients >8 to 18 years of age (3 .27 [1.11-8.12] L/h/70 kg, N=33). For pediatric patients weighing ≤45 kg, body weight normalized doxycycline CL in those ≥2 to ≤8 years of age (median [range] 0.071 [0 .041-0.202] L/kg/h, N=10) did not differ significantly from those >8 to 18 years of age (0.081 [0.035-0.126] L/kg/h, N=8). In pediatric patients weighing >45 kg, no clinically significant differences in body weight normalized doxycycline CL were observed between those ≥2 to ≤8 years (0.050 L/kg/h, N=l) and those >8 to 18 years of age (0.044 [0.014-0.121] L/kg/h, N=25). No clinically significant difference in CL between oral and IV dosing was observed in the small cohort of pediatric patients who received the oral (N=19) or IV (N=21) formulation alone. Microbiology Mechanism of Action Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. Resistance Cross resistance with other tetracyclines is common. Antimicrobial Activity Doxycycline has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section of the package insert for doxycycline hyclate tablets, USP. Gram-Negative Bacteria Acinetobacter species Bartonella bacilliformis Brucella species Klebsiella species Klebsiella granulomatis Campylobacter fetus Enterobacter aerogenes Escherichia coli Francisella tularensis Haemophilus ducrey
the following infections: Rocky Mountain spotted fevertyphus feverthe typhus group+10 more
2025
30
FLUDEOXYGLUCOSE F18
fludeoxyglucose f-18
Post-LOE
INTRAVENOUS · INJECTABLE
Radiopharmaceutical Activity
2015
30
FOSFOMYCIN TROMETHAMINE
fosfomycin tromethamine
Post-LOE
ORAL · FOR SOLUTION
CLINICAL PHARMACOLOGY Absorption Fosfomycin Tromethamine is rapidly absorbed following oral administration and converted to the free acid, fosfomycin. Absolute oral bioavailability under fasting conditions is 37%. After a single 3-gram dose of Fosfomycin Tromethamine Granules for Oral Solution, the mean (± 1 SD) maximum serum concentration (Cmax) achieved was 26.1 (± 9.1) mcg/mL within 2 hours. The oral bioavailability of fosfomycin is reduced to 30% under fed conditions. Following a single 3-gram oral dose of fosfomycin Tromethamine Granules for Oral Solution with a high-fat meal, the mean Cmax achieved was 17.6 (± 4.4) mcg/mL within 4 hours. Cimetidine does not affect the pharmacokinetics of Fosfomycin when co-administered with Fosfomycin Tromethamine Granules for Oral Solution. Metoclopramide lowers the serum concentrations and urinary excretion of fosfomycin when coadministered with Fosfomycin Tromethamine Granules for Oral Solution. (See .) Distribution The mean apparent steady-state volume of distribution (Vss) is 136.1 (±44.1) L following oral administration of Fosfomycin Tromethamine Granules for Oral Solution. Fosfomycin is not bound to plasma proteins. Fosfomycin is distributed to the kidneys, bladder wall, prostate, and seminal vesicles. Following a 50 mg/kg dose of fosfomycin to patients undergoing urological surgery for bladder carcinoma, the mean concentration of fosfomycin in the bladder, taken at a distance from the neoplastic site, was 18.0 mcg per gram of tissue at 3 hours after dosing. Fosfomycin has been shown to cross the placental barrier in animals and man. Excretion Fosfomycin is excreted unchanged in both urine and feces. Following oral administration of Fosfomycin Tromethamine Granules for Oral Solution, the mean total body clearance (CLTB) and mean renal clearance (CLR) of fosfomycin were 16.9 (± 3.5) L/hr and 6.3 (± 1.7) L/hr, respectively. Approximately 38% of a 3-gram dose of Fosfomycin Tromethamine Granules for Oral Solution is recovered from urine, and 18% is recovered from feces. Following intravenous administration, the mean CLTB and mean CLR of fosfomycin were 6.1 (±1.0) L/hr and 5.5 (± 1.2) L/hr, respectively. A mean urine fosfomycin concentration of 706 (± 466) mcg/mL was attained within 2-4 hours after a single oral 3-gm dose of Fosfomycin Tromethamine Granules for Oral Solution under fasting conditions. The mean urinary concentration of fosfomycin was 10 mcg/mL in samples collected 72-84 hours following a single oral dose of Fosfomycin Tromethamine. Following a 3-gram dose of Fosfomycin Tromethamine Granules for Oral Solution administered with a high fat meal, a mean urine fosfomycin concentration of 537 (± 252) mcg/mL was attained within 6-8 hours. Although the rate of urinary excretion of fosfomycin was reduced under fed conditions, the cumulative amount of fosfomycin excreted in the urine was the same, 1118 (± 201) mg (fed) vs. 1140 mg (± 238) (fasting). Further, urinary concentrations equal to or greater
pyelonephritisperinephric abscess
2025
30
LOCOID LIPOCREAM
hydrocortisone butyrate
LOE Approaching
TOPICAL · CREAM
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in atopic dermatitis is unknown.
atopic dermatitis
1997
30
PHENTOLAMINE MESYLATE
phentolamine mesylate
Post-LOE
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Phentolamine Mesylate for Injection, USP produces an alpha-adrenergic block of relatively short duration. It also has direct, but less marked, positive inotropic and chronotropic effects on cardiac muscle and vasodilator effects on vascular smooth muscle. Phentolamine Mesylate for Injection, USP has a half-life in the blood of 19 minutes following intravenous administration. Approximately 13% of a single intravenous dose appears in the urine as unchanged drug.
2017
30
SODIUM FLUORIDE F-18
sodium fluoride f-18
Post-LOE
INTRAVENOUS · INJECTABLE
2015
30
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT04990089VIVO European Observational Registry
N/Amobile internet survey on self-test
Susceptibility to Viral and Mycobacterial InfectionClinical Trials (1)
NCT04256395Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19
N/ASilk like Pillowcase
Acne VulgarisClinical Trials (1)
NCT00767104Efficacy of Silk - Like Bedding Fabric Pillow Case in the Treatment of Acne Vulgaris
N/Aliver transplant
Hepatocellular Carcinoma, ScirrhousClinical Trials (1)
NCT04499833HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma
N/AClariCore System
Prostate CancerClinical Trials (1)
NCT02773940ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy
N/ACommon Elements Toolbox
Depressive SymptomsClinical Trials (1)
NCT04815681Evaluating an Online Wellness Intervention for Greek Adolescents
N/AExploring a Potential Blood Test to Diagnose Major Depressive Disorder
Major Depressive DisorderClinical Trials (1)
NCT00705185Exploring a Potential Blood Test to Diagnose Major Depressive Disorder
N/AWonderlab Kids instant probiotics
ImmunityClinical Trials (1)
NCT05585021Clinical Study on the Effect of Probiotic Compound Powder on the Immunity Improvement of Preschool Children
N/AStudy product A
Overweight and ObesityClinical Trials (1)
NCT06030999The Prevention And Treatment On Obesity And Weight Management By Oral Supplementation Of Probiotics And Prebiotics
N/AQiMeiYan Probiotics
IBS - Irritable Bowel SyndromeClinical Trials (1)
NCT05900752A Multi-Strain Probiotic Reduces the Frequency of Diarrhea in IBS-D Patients
N/AChemoFx
Ovarian CancerClinical Trials (1)
NCT01048814Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
N/APBGENE-HBV
Chronic HBV InfectionClinical Trials (1)
NCT07254208A Long-term Observational Study in Participants Who Have Received PBGENE-HBV
N/AOptical coherence tomography
Optical Coherence TomographyClinical Trials (1)
NCT05517889Repeatability and Stability of Healthy Skin Features on OCT
N/AEducational program
Overweight, InfantClinical Trials (1)
NCT05121090Lille Study for Childhood Health Promotion
N/AStandardized assessments, guided tumor biopsy and biobanking
Decompensated Liver CirrhosisClinical Trials (1)
NCT06723275LEOPARD Prospective Validation Cohort 1
N/AMulti-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Biliary Tract CancerClinical Trials (1)
NCT04561453Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
N/ACustom Fabricated Splint
ArthritisClinical Trials (1)
NCT05351060Novel Splinting Technique Using 3D Models
N/AClariCore System
Prostate CancerClinical Trials (1)
NCT03734575ClariCore System Used in Transperineal Prostate Biopsy
N/AmNGS for pathogen detection
EncephalitisClinical Trials (1)
NCT02910037Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
N/AMobile Health Monitoring
HypertensionClinical Trials (1)
NCT03349918PERsonal ContExtual Precision healTh
N/ABreast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up
Breast Cancer RiskClinical Trials (1)
NCT05848856The RISC Registry--Risk Informed Screening Registry
N/AChemoFX Assay
Breast CancerClinical Trials (1)
NCT01007890Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
N/ABiological analysis, Physical examination and Questionnaires
DiabetesClinical Trials (1)
NCT05717491Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-economic Status in a Population From the North of France
N/ACMV-VST
Cytomegalovirus ViremiaClinical Trials (1)
NCT07015801CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency
N/APhase 1 Wonderlab Product
DiabetesClinical Trials (1)
NCT05756712The Efficacy of White Kidney Bean on Oral Glucose Tolerance Test
N/AScleral lens wearing keratoconics
KeratoconusClinical Trials (1)
NCT03091101Impact of Scleral Contact Lens Wear on Corneal Nerves in Keratoconus
N/AData Mining: Precision Analytical Retrospective Data Correlation
Obesity; EndocrineClinical Trials (1)
NCT04305093Data Mining: Precision Analytical Retrospective Data Correlation
N/AGynaecological laparoscopic surgery
Ovarian CancerClinical Trials (1)
NCT05048407Sirius in Gynaecological Laparoscopic Surgery
N/ABlood test: ClarityDX Prostate
Prostate CancerClinical Trials (1)
NCT03957252Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer
N/ALaboratory Biomarker Analysis
Ischemic Heart DiseaseClinical Trials (1)
NCT03064360Early Prediction of Major Adverse Cardiovascular Events Using Remote Monitoring
N/AEducation Program
StressClinical Trials (1)
NCT06063174Stress & Resilience Study
N/AA Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
Solid Organ TumorsClinical Trials (1)
NCT01271959A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
N/AWeb-based CBT
Chronic PancreatitisClinical Trials (1)
NCT03707431Internet Based Cognitive Behavioral Therapy in Pediatric Chronic Pancreatitis
N/ADermaTherapy® Linen and underpads.
Pressure UlcersClinical Trials (1)
NCT01403272Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting
N/ATissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease
Non-Small Cell Lung CancerClinical Trials (1)
NCT01450553Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease
N/AFreedom SCS System
Back PainClinical Trials (1)
NCT02514590Wireless Spinal Cord Stimulation for Chronic Pain
N/ACorrelation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Perit
Ovarian CancerClinical Trials (1)
NCT00288275Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
N/AStudy product A
OverweightClinical Trials (1)
NCT05710055The Efficacy on Overweight With Oral Supplemenation of Probiotics and Prebiotics
N/Adetect HPV E7 ctDNA
Uterine Cervical NeoplasmsClinical Trials (1)
NCT05531981Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
N/AMalariaSense device
MalariaClinical Trials (1)
NCT02672228Feasibility of the Vapor Nanobubble Technology for Malaria Diagnostics (MalariaSense)
N/ACPMRx
Opioid MisuseClinical Trials (1)
NCT05461196Decreasing Opioid Misuse and Habit-forming Behaviors Following Prescription in Patients Undergoing Cesarean Section
N/AClariCore Optical Biopsy System
Cellular Diagnosis, Prostate CancerClinical Trials (1)
NCT03504761ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation
N/AChilean Gastric Cancer Task Force (FORCE 1)
BiomarkersClinical Trials (1)
NCT03158571Chilean Gastric Cancer Task Force (FORCE 1)
N/ABiobanking with genetic analysis
Chronic Inflammatory DiseaseClinical Trials (1)
NCT04334031Deployment o the Multidisciplinary Prospective Cohort Imminent
N/AGynaecological laparoscopic surgery
Ovarian CancerClinical Trials (1)
NCT05318625A Prospective Study to Evaluate the Clinical Performance and Safety of the SIRIUS Endoscope System in Laparoscopic Gynecological Surgery.
N/AChemoFx
Endometrial CancerClinical Trials (1)
NCT01049126Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients
N/ADermaTherapy® Linen and underpads.
Pressure UlcersClinical Trials (1)
NCT01355666Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting
N/ATrio Whole Genome Sequencing and Participant-Specific Research
Rare DiseasesClinical Trials (1)
NCT04586075UW Undiagnosed Genetic Diseases Program
N/AChemoFx® PRO - A Post-Market Data Collection Study
Ovarian CancerClinical Trials (1)
NCT00669422ChemoFx® PRO - A Post-Market Data Collection Study
N/APhlebotomy
COVID-19Clinical Trials (1)
NCT04493307The Evaluation of Hemostasis in Hospitalized COVID-19 Patients
N/AOpen Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2021
Portfolio: 10 approved products, 150 clinical trials
Top TAs: Neurology, Oncology, Immunology
H-1B (2023): 1 approval
SEC Filings: 2 available
Portfolio Health
LOE Approaching2 (20%)
Post-LOE8 (80%)
10 total products
Therapeutic Area Focus
Marketed
Pipeline
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub